Reduce Cost, Cut Time, Improve Efficacy and Safety
Novoheart is a
global stem cell biotechnology
company dedicated to
engineering bioartificial human heart surrogates
using state-of-the-art bioengineering approaches.
Numbers you need to know
The impact of what Novoheart has been able to put forward cannot be understated. Our team of scientists is pioneering a new way forward for bioartificial heart tissue and organ modeling. The numbers below trumpet our success.
1st
Genetically Engineered Human Heart Cells
1st
Human
mini-heart
3
Investigational
New Drugs (IND)
25+
Years of experience
in human heart bioengineering
100+
mini-Heart related peer-reviewed publications
12+
Disease Models
Available
Our Products
Evaluating the state of cardiac health requires extensive assessment of a diverse set of functional outputs. Novoheart’s mini-Heart Platform is the ideal solution, consisting of 3 advanced engineered-tissue formats fabricated from human stem cell-derived cardiomyocytes that are designed for assessing specific cardiac functional outputs. Data acquired by the mini-Heart Platform has successfully led to a series of pre-clinical candidates as well as Investigational New Drug (IND) applications and clinical trials.
We are changing the course of research and discovery
Save Time
No Animal Dependency
Unique mini-Heart Platform
More Cost Effective
Representative Disease Models
Heart Failure with
preserved Ejection Fraction
COVID
Arrhythmias and
Long QT Syndrome
Friedreich's Ataxia
A Revolution in Human Heart Research
View the video clip for a quick summary of Novoheart’s
game changing mini-Heart Platform.
